Preimplantation Genetic Testing Market worth $1,135.0 million by 2030
The report "Preimplantation Genetic Testing Market by Product & Service (Reagents, Consumables, Instruments, Software), Technology (NGS, PCR, SNP, CGH), Procedure (Screening, Diagnosis), Application (Aneuploidy, HLA Typing), Type of cycle - Global Forecast to 2030", is expected to reach USD 1,135.0 million by 2030, up from USD 690.2 million in 2025, at a CAGR of 10.5% during the forecast period.
Browse 200 market data Tables and 45 Figures spread through 300 Pages and in-depth TOC on "Preimplantation Genetic Testing Market by Product & Service (Reagents, Consumables, Instruments, Software), Technology (NGS, PCR, SNP, CGH), Procedure (Screening, Diagnosis), Application (Aneuploidy, HLA Typing), Type of cycle - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html
The increasing prevalence of genetic disorders and infertility, along with the rising demand for assisted reproductive technologies, is fueling the growth of the preimplantation genetic testing market. The focus on preventing the transmission of hereditary diseases and improving success rates in in vitro fertilization further boosts market expansion. Moreover, advancements in genetic sequencing and embryo screening technologies are improving diagnostic accuracy, making PGT a vital part of reproductive medicine and personalized healthcare.
Preimplantation genetic screening is expected to hold the largest share during the forecast period.
The preimplantation genetic testing market is divided by procedure type into preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). This growth is primarily driven by the increasing use of PGS to detect chromosomal abnormalities before embryo transfer. End users, such as fertility clinics and IVF centers, are increasingly adopting comprehensive, high-throughput screening methods to boost implantation success and lessen the chance of genetic disorders. The adoption of next-generation sequencing (NGS) and array-based platforms has greatly enhanced accuracy, speed, and dependability. Moreover, ongoing product innovations and the availability of automated, ready-to-use screening options are further encouraging adoption in clinical environments.
The next-generation sequencing segment is expected to hold the largest share during the forecast period.
By technology, the preimplantation genetic testing market is segmented into next-generation sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP) analysis. The next-generation sequencing (NGS) segment accounted for the largest share of the preimplantation genetic testing market in 2024 and is expected to maintain its dominance during the forecast period. The market’s growth is driven by the increasing adoption of NGS for comprehensive chromosomal and single-gene disorder screening in embryos prior to implantation.
By enabling high-throughput analysis and precise detection of genetic abnormalities, NGS offers superior accuracy, sensitivity, and resolution compared to traditional techniques such as FISH and PCR. The technology enables the simultaneous screening of multiple genetic conditions, significantly enhancing embryo selection and improving IVF success rates. Additionally, ongoing improvements in sequencing platforms and bioinformatics tools are boosting workflow efficiency, making NGS-based preimplantation testing a key technique in precision reproductive medicine.
The Asia Pacific is expected to be the fastest-growing region during the forecast period.
The APAC region is expected to see the fastest growth in the preimplantation genetic testing market. This growth is driven by the rising rates of infertility, increased awareness of genetic diseases, and greater adoption of assisted reproductive technologies like IVF. Additionally, government initiatives focused on enhancing reproductive healthcare and increasing access to advanced fertility treatments are further fueling market expansion. Moreover, leading international and regional companies are strengthening their presence through collaborations, partnerships, and technology integrations to seize emerging opportunities across the region.
Key players in the preimplantation genetic testing market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), CooperCompanies (US), Revvity (US), Abbott (US), Takara Bio Inc. (Japan), and QIAGEN (Germany), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Preimplantation Genetic Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
